HR 2182

112th CONGRESS
1st Session

H. R. 2182

To provide incentives for the development of qualified infectious disease products.

IN THE HOUSE OF REPRESENTATIVES

June 15, 2011

Mr. GINGREY of Georgia (for himself, Mr. GENE GREEN of Texas, Mr. WHITFIELD, Ms. DEGETTE, Mr. ROGERS of Michigan, Ms. ESHOO, and Mr. SHIMKUS) introduced the following bill; which was referred to the Committee on Energy and Commerce


A BILL

To provide incentives for the development of qualified infectious disease products.

SECTION 1. SHORT TITLE.

SEC. 2. TABLE OF CONTENTS.

SEC. 3. EXTENSION OF EXCLUSIVITY PERIOD FOR DRUGS.

`SEC. 505E. EXTENSION OF EXCLUSIVITY PERIOD FOR NEW QUALIFIED INFECTIOUS DISEASE PRODUCTS.

SEC. 4. ADDITIONAL EXTENSION OF EXCLUSIVITY PERIOD FOR QUALIFIED INFECTIOUS DISEASE PRODUCTS FOR WHICH A COMPANION DIAGNOSTIC TEST IS CLEARED OR APPROVED.

`SEC. 505E-1. ADDITIONAL EXTENSION OF EXCLUSIVITY FOR QUALIFIED INFECTIOUS DISEASE PRODUCTS FOR WHICH A COMPANION DIAGNOSTIC TEST IS CLEARED OR APPROVED.

SEC. 5. PRIORITY REVIEW.

`SEC. 524A. PRIORITY REVIEW FOR QUALIFIED INFECTIOUS DISEASE PRODUCTS.

SEC. 6. FAST TRACK PRODUCT.

SEC. 7. STUDY ON INCENTIVES FOR QUALIFIED INFECTIOUS DISEASE BIOLOGICAL PRODUCTS.

SEC. 8. CLINICAL TRIALS.

END